experience with ABSORB BRS was reassuring as far as safety concerns, but the first worrisome data, regarding an increased risk of stent thrombosis, aroused from the European Multicenter Registry GHOST-EU (Gauging coronary Healing with bioresorbable Scaffolding plaTforms in Europe). 5 Data from the registry, in fact, demonstrated a device thrombosis rate of 2.1% at 6 months, which jeopardized patients safety when compared with the outcome previously observed with first-generation drug-eluting stents. 6 The increased risk of stent thrombosis has been confirmed by the results of various randomized clinical trials. A recent meta-analysis by Sorrentino et al, 7 based on seven clinical trials comparing BRS and EES, outlined a temporal trend for the risk of thrombosis constantly increasing during the early and very late phases after the procedure ( Figure 1 ). Mechanisms potentially associated with the increased risk of thrombosis with ABSORB BRS include the device structure and 'scaffold dismantling'. The thickness of the struts is noteworthy, considering that the latest generation metal stents reach a thickness of 60-80 mm.
Experimental models and computer analysis demonstrated that the thickness of the struts influences turbulence of blood flow after stent implant in a manner directly proportional to the struts protrusion inside the vessel lumen. 8 'Scaffold dismantling', defined as an anomalous reabsorption process of not completely endothelialized struts, implies the collapse of the struts inside the vessel lumen during the reabsorption process. 9 Not all the news is bad. A significant reduction of the incidence of thrombosis has been demonstrated when the technical details of the implant procedure are carefully respected. The structural limitations determining an increased risk of thrombosis after BRS are amplified by suboptimal implantation technique (malapposition, edge dissection, etc.), or inappropriate selection of complex lesions (small caliber vessel, long calcific lesions, scaffolds overlapping). It has been proven that the implant assisted by intravascular imaging modalities, the careful preparation of the lesion (1:1 ratio between pre-dilation balloon and scaffold diameter, no significant residual stenosis), as well as the correct sizing of the device, and the postdilation after the implant (PSP technique), could all significantly mitigate the risk of thrombosis. 10, 11 Of particular interest are the 5 years results of ABSORB trial, recently published. 12 After complete device reabsorption, the outwards vessel remodelling was more significant and frequent for the ABSORB BRS when compared with metal stents. Likewise was documented the complete recuperation of the jailed lateral branches at the bifurcation site. 13 Encouraging results, as far as thrombogenicity, are emerging for the new magnesium BRS. Table 2 depicts the main BRS so far utilized in clinical practice, and the future devices still under development. Current technology developments aim at decrease thrombogenicity, improve mechanical properties by utilizing molecules other than poly-lactic acid, and, possibly, reducing the time necessary for complete reabsorption of the device, so as to anticipate the possible benefits over the metal stents.
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